Reuters logo
4 years ago
Bayer submits Eylea for new indication in Japan
November 28, 2013 / 7:11 AM / 4 years ago

Bayer submits Eylea for new indication in Japan

FRANKFURT, Nov 28 (Reuters) - Bayer has submitted its Eylea eye medication, co-developed with Regeneron, for approval in Japan to treat Myopic Choroidal Neovascularization (myopic CNV), a cause of blindness.

In Japan, pathologic myopia and the associated myopic CNV is one of the most common causes of blindness, Bayer said.

Eylea, which also treats age-related macular degeneration (AMD) - the most common cause of blindness in the elderly - has been grabbing market share from rivals such as Roche AG's Lucentis since its launch in late 2011.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below